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Abstract 
This article updates the Heart Failure Association of the European Society of Cardiology (ESC) 2007 
classification of advanced heart failure and describes new diagnostic and treatment options for these patients. 
Recognizing the patient with advanced heart failure is critical to facilitate timely referral to advanced heart 
failure centres. Unplanned visits for heart failure decompensation, malignant arrhythmias, co‐morbidities, and 
the 2016 ESC guidelines criteria for the diagnosis of heart failure with preserved ejection fraction are 
included in this updated definition. Standard treatment is, by definition, insufficient in these patients. 
Inotropic therapy may be used as a bridge strategy, but it is only a palliative measure when used on its own, 
because of the lack of outcomes data. Major progress has occurred with short‐term mechanical circulatory 
support devices for immediate management of cardiogenic shock and long‐term mechanical circulatory 
support for either a bridge to transplantation or as destination therapy. Heart transplantation remains the 
treatment of choice for patients without contraindications. Some patients will not be candidates for advanced 
heart failure therapies. For these patients, who are often elderly with multiple co‐morbidities, management of 
advanced heart failure to reduce symptoms and improve quality of life should be emphasized. Robust 
evidence from prospective studies is lacking for most therapies for advanced heart failure. There is an urgent 
need to develop evidence‐based treatment algorithms to prolong life when possible and in accordance with 
patient preferences, increase life quality, and reduce the burden of hospitalization in this vulnerable patient 
population. 
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Introduction 
Although patients with chronic heart failure have improved outcomes with implementation of 
evidence‐based therapies, ultimately, they still progress to an advanced stage of the disease. 
Patients with advanced heart failure comprise an estimated 1% to 10% of the overall heart failure 
population,
1-3
 and the prevalence is increasing due to the growing number of patients with heart 
failure and their better treatment and survival. A thorough definition of advanced heart failure is 
mandatory to facilitate appropriate application of treatment such as heart transplantation or long‐
term mechanical circulatory support (MCS) devices.  
 
It is often a general cardiologist who is responsible for directing patients to advanced heart 
failure resources and helping patients navigate next steps in care. Thus, clinicians need to be 
appropriately equipped to identify patients that might be candidates for advanced heart failure 
therapies and to recognize the optimal time for referral. Of equal importance, physicians should be 
prepared to address the needs of patients who are clearly not eligible for advanced heart failure 
therapies, engage in discussions about changing goals of care, and optimize management strategies 
to lessen the symptomatic burden of advanced heart failure and improve quality of life. 
 
The management of patients with heart failure to improve their quality of life and longevity is a 
mission of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). In 
this context, the HFA has prepared this position document to (i) describe the clinical 
characteristics of patients with advanced heart failure, (ii) inform physicians about markers of poor 
prognosis that indicate an advanced stage of disease, (iii) educate physicians on optimal short‐term 
management strategies for these patients in order to improve their candidacy for heart 
transplantation or MCS, (iv) enable physicians to recognize the optimal time and processes for 
referring patients to advanced heart failure centres, and (v) ensure collaboration between advanced 
heart failure, palliative or symptom‐focused care including end‐of‐life care teams. This position 
statement summarizes the best available evidence, practice standards, and expert opinions on the 
management of patients with advanced heart failure. This article is intended to guide general 
cardiologists, heart failure cardiologists and other professionals involved in the care of these 
patients such as internists, primary care physicians, and nurses through transitions in care.  
Definition of advanced heart failure 
Prior definitions for patients with advanced heart failure are shown in Table 1.
3-6
 The criteria 
suggested in the 2007 HFA position statement identified a stage where conventional treatments 
(i.e. guideline‐directed drugs, devices, conventional surgery) are insufficient to control the 
patient's symptoms, and advanced therapies (e.g. cardiac transplantation, MCS) or palliative 
therapies (e.g. inotropic infusions, ultrafiltration or peritoneal dialysis to control volume, or end‐
of‐life comfort care) are needed. Overlapping terminology can be used to describe these patients; 
for the purpose of this document, we consider ‘advanced’, ‘refractory’, and ‘end‐stage’ heart 
failure interchangeable terms, all reflecting patients who should be evaluated for advanced heart 
failure therapies. The Interagency Registry for Mechanically Assisted Circulatory Support 
(INTERMACS) profiles are also useful to further describe clinical parameters and characteristics 
consistent with a need for advanced therapies (Table 2).
7-9
 However, it must be noted that the 
INTERMACS profiles were developed to classify patients to being considered for long‐term MCS 
device implantation based on symptoms and haemodynamic compromise and, more important, is 
specific for heart failure with reduced ejection fraction (HFrEF), whereas our classification and, in 
general, the term of advanced heart failure can be applied also to patients with heart failure with 
preserved ejection fraction (HFpEF). 
 
Table 1. Prior definitions and indicators of advanced heart failure 
Heart Failure Association4 
American College of Cardiology/American Heart 
Association5, 6 
Heart Failure Society of America3 
   
1. Severe symptoms of HF with dyspnoea and/or fatigue 
at rest or with minimal exertion (NYHA functional 
class III or IV) 
2. Episodes of fluid retention (pulmonary and/or systemic 
congestion, peripheral oedema) and/or of reduced 
cardiac output at rest (peripheral hypoperfusion) 
3. Objective evidence of severe cardiac dysfunction, 
shown by at least one of the following:  
(a) A low LVEF (<30%) 
(b) A severe abnormality of cardiac function on 
Doppler echocardiography with a pseudonormal 
or restrictive mitral inflow pattern 
(c) High LV filing pressures (mean PCWP >16 
mmHg, and/or mean RAP >12 mmHg by 
pulmonary artery catheterization) 
(d) High BNP or NT‐proBNP plasma levels, in the 
absence of non‐cardiac causes 
4. Severe impairment of functional capacity shown by 
one of the following:  
(a) Inability to exercise 
(b) 6MWT distance <300 m or less in females and/or 
patients aged ≥75 years 
(c) Peak VO2 <12 to 14 mL/kg/min  
5. History of ≥1 HF hospitalization in the past 6 months 
6. Presence of all the previous features despite ‘attempts 
to optimize’ therapy including diuretics, inhibitors of 
the renin–angiotensin–aldosterone system, and beta‐
blockers, unless these are poorly tolerated or 
contraindicated, and CRT, when indicated 
1. Repeated (≥2) hospitalizations or ED 
visits for HF in the past year 
2. Progressive deterioration in renal 
function (e.g. rise in BUN and creatinine) 
3. Weight loss without other cause (e.g. 
cardiac cachexia) 
4. Intolerance to ACE inhibitors due to 
hypotension and/or worsening renal 
function 
5. Intolerance to beta‐blockers due to 
worsening HF or hypotension 
6. Frequent systolic blood pressure <90 
mmHg 
7. Persistent dyspnoea with dressing or 
bathing requiring rest 
8. Inability to walk 1 block on the level 
ground due to dyspnoea or fatigue 
9. Recent need to escalate diuretics to 
maintain volume status, often reaching 
daily furosemide equivalent dose >160 
mg/day and/or use of supplemental 
metolazone therapy 
10. Progressive decline in serum sodium, 
usually to <133 mEq/L 
11. Frequent ICD shocks 
The presence of progressive and/or persistent severe signs and symptoms of HF despite 
optimized medical, surgical, and device therapy. It is generally accompanied by frequent 
hospitalization, severely limited exertional tolerance, and poor quality of life and is 
associated with high morbidity and mortality. Importantly, the progressive decline should be 
primarily driven by the HF syndrome. 
Indicators of advanced HF in the setting of optimal medical and electrical therapies that 
should trigger consideration of referral for evaluation of advanced therapies include:  
 Need for intravenous inotropic therapy for symptomatic relief or to maintain end‐
organ function 
 Peak VO2 <14 mL/kg/min or <50% of predicted  
 6MWT distance <300 m 
 ≥2 HF admissions in the last 12 months 
 >2 unscheduled visits (e.g. ED or clinic) in the last 12 months 
 Worsening right HF and secondary pulmonary hypertension 
 Diuretic refractoriness associated with worsening renal function 
 Circulatory–renal limitation to RAAS inhibition or beta‐blocker therapy 
 Progressive/persistent NYHA functional class III–IV symptoms 
 Increased 1‐year mortality (e.g. 20–25%) predicted by HF survival models (e.g. 
SHFS, HFSS, etc.) 
 Progressive renal or hepatic end‐organ dysfunction 
 Persistent hyponatraemia (serum sodium <134 mEq/L) 
 Recurrent refractory ventricular tachyarrhythmias; frequent ICD shocks 
 Cardiac cachexia 
 Inability to perform ADL 
   
 
6MWT, 6‐minute walk test; ACE, angiotensin‐converting enzyme; ADL, activities of daily living; BNP, B‐type natriuretic peptide; BUN, blood urea nitrogen; CRT, cardiac resynchronization therapy; ED, 
emergency department; HF, heart failure; HFSS, Heart Failure Survival Score; ICD, implantable cardioverter‐defibrillator; LV, left ventricular; LVEF, left ventricular ejection fraction; NT‐proBNP, N‐terminal 
pro‐B‐type natriuretic peptide; NYHA, New York Heart Association; PCWP, pulmonary capillary wedge pressure; RAAS, renin–angiotensin–aldosterone system; RAP, right atrial pressure; SHFS, Seattle 
Heart Failure Score; VO2, oxygen consumption. 
  
Table 2. Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) profile descriptions in patients with advanced heart failure 
Profile Time frame for intervention 
  
Profile 1: Critical cardiogenic shock 
Patient with life‐threatening hypotension despite rapidly escalating inotropic support, critical organ hypoperfusion, often confirmed by worsening acidosis and/or 
lactate levels. “Crash and burn.” 
Definitive intervention needed within 
hours. 
Profile 2: Progressive decline 
Patient with declining function despite intravenous inotropic support, may be manifest by worsening renal function, nutritional depletion, inability to restore volume 
balance. “Sliding on inotropes.” Also describes declining status in patients unable to tolerate inotropic therapy. 
Definitive intervention needed within few 
days. 
Profile 3: Stable but inotrope‐dependent 
Patient with stable blood pressure, organ function, nutrition, and symptoms on continuous intravenous inotropic support (or a temporary circulatory support device or 
both), but demonstrating repeated failure to wean from support due to recurrent symptomatic hypotension or renal dysfunction. “Dependent stability.” 
Definitive intervention elective over a 
period of weeks to few months. 
Profile 4: Resting symptoms 
Patient can be stabilized close to normal volume status but experiences daily symptoms of congestion at rest or during ADL. Doses of diuretics generally fluctuate at 
very high levels. More intensive management and surveillance strategies should be considered, which may in some cases reveal poor compliance that would 
compromise outcomes with any therapy. Some patients may shuttle between 4 and 5. 
Definitive intervention elective over a 
period of weeks to few months. 
Profile 5: Exertion intolerant 
Comfortable at rest and with ADL but unable to engage in any other activity, living predominantly within the house. Patients are comfortable at rest without 
congestive symptoms, but may have underlying refractory elevated volume status, often with renal dysfunction. If underlying nutritional status and organ function are 
marginal, patients may be more at risk than INTERMACS 4, and require definitive intervention. 
Variable urgency, depends upon 
maintenance of nutrition, organ function, 
and activity. 
Profile 6: Exertion limited 
Patient without evidence of fluid overload is comfortable at rest, and with ADL and minor activities outside the home but fatigues after the first few minutes of any 
meaningful activity. Attribution to cardiac limitation requires careful measurement of peak oxygen consumption, in some cases with haemodynamic monitoring to 
confirm severity of cardiac impairment. “Walking wounded.” 
Variable, depends upon maintenance of 
nutrition, organ function, and activity 
level. 
Profile 7: Advanced NYHA class III 
A placeholder for more precise specification in future, this level includes patients who are without current or recent episodes of unstable fluid balance, living 
comfortably with meaningful activity limited to mild physical exertion. 
Transplantation or circulatory support 
may not currently be indicated. 
Modifiers for profiles Possible profiles to modify 
TCS‐Temporary Circulatory Support can modify only patients in hospital (other devices would be INTERMACS devices). This includes IABP, ECMO, 
TandemHeart, Levitronix, BVS 5000 or AB5000, Impella. 
1, 2, 3 in hospital. 
A‐Arrhythmia can modify any profile. Recurrent ventricular tachyarrhythmias that have recently contributed substantially to clinical compromise. This includes 
frequent ICD shocks or requirement for external defibrillator, usually more than twice weekly. 
Any profile. 
FF‐Frequent Flyer can modify only outpatients, designating a patient requiring frequent emergency visits or hospitalizations for diuretics, ultrafiltration, or temporary 
intravenous vasoactive therapy. 
3 if at home, 4, 5, 6. A Frequent Flyer 
would rarely be profile 7. 
  
 
ADL, activities of daily living; ECMO, extracorporeal membrane oxygenation; IABP, intra‐aortic balloon pump; ICD, implantable cardioverter‐defibrillator; NYHA, New York Heart Association. 
Reprinted with permission from Stevenson et al.8 
Limitations of the 2007 Heart Failure Association position statement for advanced chronic heart 
failure 
Advanced heart failure encompasses patients who remain severely symptomatic despite optimal 
guideline‐directed management regardless of left ventricular ejection fraction (LVEF), including patients 
with advanced heart failure who remain ambulatory but are essentially New York Heart Association 
(NYHA) class IV. The first HFA position statement acknowledged the importance of HFpEF and 
included a provision to diagnose advanced heart failure on the basis of high B‐type natriuretic peptide 
(BNP) or N‐terminal pro‐BNP (NT‐proBNP) levels independently of LVEF values.4 Despite this 
recognition, advanced symptoms in the setting of HFpEF were not emphasized sufficiently to meet 
current clinical practice needs. It is important to raise awareness that advanced heart failure does not 
depend on ejection fraction, but on the patient's symptoms, prognostic markers, presence of end‐organ 
damage, and goals for therapy.  
 
The treatment armamentarium has improved for HFrEF since the 2007 HFA document, with clearer 
indications for cardiac resynchronization therapy (CRT) and the availability of new drugs, such as 
ivabradine and sacubitril/valsartan, although to date, no trial has specifically addressed patients with 
advanced heart failure. The need to optimize such therapies should be reflected in definitions of advanced 
heart failure, and patients must be treated according to the best available medical and device therapies 




Further criteria must also be considered. First, outpatient visits with intravenous administration of 
loop diuretics and/or other vasoactive medications are increasingly replacing hospitalizations for heart 
failure.
11 
Thus, both unplanned outpatient visits and hospitalizations for worsening symptoms of heart 
failure must be considered amongst criteria for the diagnosis of advanced heart failure to reflect evolving 
clinical practice. Second, recurrent malignant arrhythmias are now well recognized contributors to and 
can be consequences of advanced heart failure.
12-14 
Third, co‐morbidities can complicate the evaluation of 
patients with advanced heart failure, and sometimes influence candidacy for MCS or heart 
transplantation, although it should be recognized that in some cases co‐morbidities may improve after 
application of advanced therapies.
15-18
 End‐organ damage, in particular kidney or liver dysfunction and 
pulmonary hypertension, may be a consequence of acute congestion and/or low‐output state, but it may be 
difficult to distinguish primary and secondary dysfunction or to predict reversibility.  
Updated definition of advanced heart failure 
To address these areas, an update to the definition of advanced heart failure is warranted. Our updated 
criteria for the identification of patients with advanced heart failure are outlined in Table 3. Compared 
with the former HFA definition of advanced heart failure, we have updated the following criteria:  
 
 Criterion 2 is now based completely on the most recent ESC heart failure guidelines.9 The ESC 
criteria are sufficient to define cardiac dysfunction, and they can be used for the definition of 
advanced heart failure when accompanied by other criteria that characterize patient severity. 
Using the ESC criteria for cardiac dysfunction gives the same importance to all patients with 
heart failure, independent of LVEF. With a few exceptions, such as patients with hypertrophic 
cardiomyopathy or restrictive cardiomyopathy,
19
 the vast majority of patients with an indication 
for heart transplantation or MCS have a reduced LVEF. However, at least 50% of patients 
hospitalized for acute heart failure have a preserved LVEF, and these patients may also be 
considered advanced provided the other criteria outlined in the definition are present.  
  
 Criterion 3 now includes heart failure hospitalization. Unplanned visits for heart failure have 
been added and given the same value as a heart failure hospitalization.
20-23
 Malignant 
arrhythmias have been added as a major cause of acute events. Criterion 3 acknowledges that 
acute events leading to one or more unplanned visit(s) or hospitalization(s) within 12 months are 
the hallmark of advanced heart failure, independent of treatment, with emphasis placed on the 
instability of the clinical course and resource utilization.  
Table 3. Updated HFA‐ESC criteria for defining advanced heart failure 
 
All the following criteria must be present despite optimal guideline‐directed treatment: 
1. Severe and persistent symptoms of heart failure [NYHA class III (advanced) or IV]. 
2. Severe cardiac dysfunction defined by a reduced LVEF ≤30%, isolated RV failure (e.g. ARVC) or non‐operable severe 
valve abnormalities or congenital abnormalities or persistently high (or increasing) BNP or NT‐proBNP values and data 
of severe diastolic dysfunction or LV structural abnormalities according to the ESC definition of HFpEF and HFmrEF.9 
3. Episodes of pulmonary or systemic congestion requiring high‐dose intravenous diuretics (or diuretic combinations) or 
episodes of low output requiring inotropes or vasoactive drugs or malignant arrhythmias causing >1 unplanned visit or 
hospitalization in the last 12 months. 
4. Severe impairment of exercise capacity with inability to exercise or low 6MWTD (<300 m) or pVO2 (<12–14 
mL/kg/min), estimated to be of cardiac origin.  
 
In addition to the above, extra‐cardiac organ dysfunction due to heart failure (e.g. cardiac cachexia, liver, or kidney dysfunction) or 
type 2 pulmonary hypertension may be present, but are not required. 
Criteria 1 and 4 can be met in patients who have cardiac dysfunction (as described in criterion #2), but who also have substantial 
limitation due to other conditions (e.g. severe pulmonary disease, non‐cardiac cirrhosis, or most commonly by renal disease with 
mixed aetiology). These patients still have limited quality of life and survival due to advanced disease and warrant the same 




ARVC, arrhythmogenic right ventricular cardiomyopathy; BNP, B‐type natriuretic peptide; ESC, European Society of Cardiology; 
HFA, Heart Failure Association; HFmrEF, heart failure with mid‐range ejection fraction; HFpEF, heart failure with preserved 
ejection fraction; LV, left ventricular; LVEF, left ventricular ejection fraction; NT‐proBNP, N‐terminal pro‐B‐type natriuretic 
peptide; NYHA, New York Heart Association; pVO2, peak exercise oxygen consumption; RV, right ventricular; 6MWTD, 6‐minute 
walk test distance. 
Prognostic stratification 
Accurate prognostication is especially important in advanced heart failure to identify the ideal time for 
referral to an appropriate centre (i.e. those centres capable of providing advanced heart failure therapies), 
to properly convey expectations to patients and families, and to plan treatment and follow‐up strategies.24, 
25
 However, detailed prognostication is complex and difficult. It is required for selection for advanced 
heart failure therapy, but it is not required for referral to an advanced heart failure centre. Referral 
requires only the presence of advanced heart failure. Numerous single risk markers and composite risk 
scores have been derived, validated, and are available as interactive online tools. These multiparametric 
scores can assist the heart failure team in arriving at comprehensive risk assessments to inform decisions.
9 
However, there are several important considerations and limitations that are often overlooked when 
applying these tools in clinical settings and in clinical trial design.  
 
First, many prognostic tools were derived and validated in selected clinical trial populations or at 
single centres and may not be generalizable to ‘real‐world’ heart failure populations or individual 
patients. Second, most of the available tools for estimating prognosis were not derived from advanced 
heart failure cohorts. Third, risk markers and scores perform well for mortality but less well for 
cardiovascular or heart failure specific death or hospitalization.
9, 26-28
 Fourth, not all risk markers are also 
risk factors. Thus, targeting a risk marker will not automatically improve outcomes. One example 
includes pharmacologic interventions targeting haemodynamics, which do not correct the underlying 
aetiology of heart failure and do not improve outcome, although an impaired haemodynamic profile is a 
very powerful indicator of poor prognosis. Finally, appropriate clinical use of any prognostic variable 
(biomarker) or multiparametric score requires understanding of discrimination (between event and non‐
event), calibration (predicted vs. actual outcome), and reclassification (how well addition of information 
correctly reclassifies events).
24
 For example, NT‐proBNP discriminates very well (i.e. higher values 
accurately predict greater heart failure risk), but it calibrates poorly because there is no particular value of 
NT‐proBNP that corresponds to a particular expected mortality rate or that can be used to list a patient for 
cardiac transplantation. Finally, it must be kept in mind that different prognostic scores may perform 





Nevertheless, objective risk markers and scores, especially as part of a comprehensive assessment 
performed by the heart failure team, are useful for prognostication, prioritization, and triage for advanced 
heart failure interventions, including selection for cardiac transplantation.
25
 It is useful to consider risk 
markers from multiple pathophysiological domains (Table 4)
.8, 25, 27, 28, 30-127
 Clinical history such as 
recurrent heart failure hospitalizations, and the physician's impression from the patient encounter are 
critical. An expanding spectrum of parameters are available from echocardiography and other imaging 
modalities, and they may serve not only for prognostication but also to guide patient management, 
gradually taking the place of right heart catheterization, though with some limitations.
128, 129
 Invasive 
haemodynamic assessment does not improve the accuracy of heart failure prognostication, but it is a 
critical component of the work‐up for potential heart transplantation or long‐term MCS recipients. It 
allows an accurate estimate of important parameters, such as the pulmonary capillary wedge pressure, 
pulmonary vascular resistance, transpulmonary gradient, and adds to the assessment of right ventricular 
function.
25, 130, 131
 Invasive haemodynamic monitoring is not routinely recommended for in‐hospital 
management of patients with advanced heart failure,
132 
but it is useful for the evaluation and treatment of 
patients in critical conditions, e.g. cardiogenic shock, not responding to standard treatment. The 
cardiopulmonary exercise test (CPET) provides a set of integrated parameters that are impacted by 
cardiac, pulmonary, peripheral and psychological factors, and it is a critical component of the work‐up in 
patients with advanced heart failure who are able to perform the test. Co‐morbidities are common and 
important prognostic markers in heart failure. In selecting advanced heart failure interventions, physicians 
should consider both prognosis without therapy (indication) and the potential for adverse outcomes with 
interventions (contraindications). Contraindications are often related to co‐morbidities that cannot be 
modified by heart failure therapy and predispose patients to adverse outcomes after heart transplantation 
or MCS. End‐organ dysfunction such as chronic kidney disease (CKD) may be intrinsic or secondary to 
heart failure. Liver dysfunction in the setting of advanced heart failure has been less extensively 
investigated than renal insufficiency. The most common indices of acute and chronic liver damage due to 
congestive and/or low‐output state are increased transaminase levels (AST, ALT) and increased serum 
bilirubin, respectively.
16
 End‐organ damage impacts outcomes, and it is important for the heart failure 
team to assess whether such damage is likely reversible after transplantation or MCS. Other co‐
morbidities, such as disordered iron metabolism, must be systematically investigated9 as treatment may 









↑ QRS duration32, 33 
Longer HF duration30 
Higher NYHA class34-37 
Lower and labile SBP and lower DBP and MAP30, 38-40 
Lower pulse pressure41 
↑ HR in sinus rhythm but not in atrial fibrillation30, 42-44 
Reduced HR variability45-47 
Recent /recurrent HF hospitalizations30 
Haemodynamic profiles48, 49 
Cardiomegaly30 
S350 
Poor quality of life 






Laboratory and biomarkers121 





Higher BNP and/or NT‐proBNP56, 58-62 


















Large areas of hypo/akinesis 
LV dilatation74 
Diastolic dysfunction75, 76 
Mitral regurgitation30 
Aortic stenosis 
LV hypertrophy72, 77 
LV mass72 
Left atrial enlargement72, 78, 79 
Right ventricular function80, 81 
Pulmonary hypertension80, 82 
Resting dobutamine stress strain83, 84 
Other imaging 
Pulmonary congestion by lung ultrasound85 
Inflammation and fibrosis on CMR 
Poor viability on stress echo and CMR84 
Reduced miBG uptake86, 87 
Cardiopulmonary exercise test 
pVO2
59, 88 





Ischaemic heart disease/prior myocardial infarction30 
Prior transient ischaemic attack/stroke 
Peripheral arterial disease 
Atrial fibrillation30 
Ventricular arrhythmia, sudden cardiac death, ICD 
shocks 
Non‐cardiovascular 
Chronic kidney disease89, 90 
Diabetes30 
Chronic obstructive pulmonary disease 
Smoking30 
Anaemia91 
Higher red cell distribution width92 
Higher white blood cell count93 
Iron deficiency 
Liver dysfunction and low albumin94, 95 
Sleep apnoea and Cheyne–Stokes breathing 
Depression96-98 
Frailty99 
Cachexia30, 100, 101 
Cognitive dysfunction102 
Diuretic resistance 









Treatment and organization‐related factors 
Poor guideline adherence119 
 
6MWT, 6‐min walk test; CPET, cardiopulmonary exercise test; CRT, cardiac resynchronization therapy; eGFR, estimated 
glomerular filtration rate; GDMT, guideline‐directed medical therapy; Hb, haemoglobin; HF, heart failure; IVC, inferior vena cava; 
K, potassium; KCCQ, Kansas City Cardiomyopathy Questionnaire; LVEF, left ventricular ejection fraction; MAGGIC, Meta‐
Analysis Global Group in Chronic Heart Failure; MLHFQ, Minnesota Living with Heart Failure Questionnaire; Na, sodium; NT‐
proBNP, N‐terminal pro‐B‐type natriuretic peptide; NYHA, New York Heart Association; PA, pulmonary artery; RV, right 
ventricular; SBP, blood pressure; SCr, serum creatinine; SHFM, Seattle Heart Failure Model. 
* Note that this table reflects many clinically relevant but sometimes subjective and non‐specific criteria. With these criteria, 
sensitivity has been prioritized over specificity, i.e. many criteria may be present in patients who do not need referral, but by 
considering these criteria in a comprehensive assessment, there is a lower risk that high‐risk patients may be missed or referred too 
late. While cut‐offs exist for transplantation listing or left ventricular assist device implantation, there are no data to support specific 
cut‐offs for referral to a HF centre.  
† Moderate mitral regurgitation alone is not sufficient, but is one factor suggesting risk of progression and should be considered 
together with other variables.  
Finally, non‐patient‐related factors, such as organization of care and access to treatment and follow‐
up, are also strongly associated with outcomes. Despite the availability of an extensive set of prognostic 
parameters, predicting outcomes both in the absence and presence of advanced heart failure interventions 
remains difficult, and patients are often referred to advanced heart failure centres too late. The concept of 
active screening for advanced intervention has been proposed to improve appropriate referral and 
treatment in advanced heart failure
139, 140




Figure 1. Triage of patients with advanced heart failure (HF) and appropriate timing of referral. ARNI, angiotensin receptor–
neprilysin inhibitor; COPD, chronic obstructive pulmonary disease; CRT, cardiac resynchronization therapy; ICD, implantable 
cardioverter‐defibrillator; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association; RAS, renin–angiotensin 
system; SBP, systolic blood pressure; SCr, serum creatinine. 
  
Exercise testing 
Cardiopulmonary exercise testing is reproducible and provides important information about 
cardiovascular reserve and prognosis. Traditionally, CPET has been part of the evaluation of ambulatory 
patients with advanced heart failure if they were considered for heart transplantation or long‐term MCS. 
Guidelines for listing elective patients for heart transplantation still state that a peak exercise oxygen 
consumption (pVO2) ≤12 mL/kg/min is a potential indication for heart transplantation (≤14 if beta‐
blocker intolerant).
25
 Importantly, confirmation that peak values have been achieved is mandatory, for 
instance by ensuring a respiratory exchange rate >1.05. In addition to pVO2, other CPET findings may 
help inform the evaluation of heart transplantation candidacy. In women or patients <50 years of age, 
achieving a pVO2 ≤50% of predicted may be appropriate to determine heart transplant referral.
25 
Additionally, patients with a ventilation equivalent of carbon dioxide (VE/VCO2) slope >35, particularly 
those with a submaximal CPET, have a poor prognosis, and VE/VCO2 slope may be applied in the patient 
evaluation.
25 
Performing high quality CPET is not a simple task and reliable results require staff skilled in 
the procedure as well as meticulous interpretation.
141
 However, CPET remains highly valuable to identify 
patients with potential indications for heart transplantation or long‐term MCS and should be part of the 
work‐up for elective patients with advanced heart failure in whom these treatments are considered, 




The 6‐min walk test (6MWT) is easy to perform and widely used in heart failure. It should be 
emphasized that CPET and 6MWT are very different measures. Peak oxygen uptake during CPET 
expresses maximal cardiac output and the arteriovenous oxygen difference during maximal exhaustion, 
while the 6MWT is performed at submaximal exercise levels. Thus, the 6MWT does not accurately 
reflect functional capacity as assessed by pVO2,
127
 but it is correlated to pVO2 and predicts survival in 
heart failure in some,
127 
but not all studies.
143-145
 The 6MWT has been used as a screening tool in 
advanced heart failure (<300 m) and also as an endpoint in clinical trials. Use of the 6MWT is encouraged 
to give objective evidence of functional impairment in patients with advanced heart failure where CPET 
is not indicated as described above. In addition, the 6MWT can be a useful tool to assess frailty, which 




Management strategies for patients with advanced heart failure 
Short‐term management of advanced heart failure 
Advanced heart failure therapies refer to long‐term MCS or cardiac transplantation. However, in 
situations where the patient's clinical condition deteriorates, or end‐organ function is compromised, short‐
term therapies may be needed until MCS can be implanted or while the patient is waiting on the 
transplant list. Discussion of the patient and overall plan for advanced heart failure therapies with a 
specialized advanced heart failure centre (i.e. hub centre) can be helpful to select the most appropriate 
short‐term management strategy. 
Intravenous vasoactive drugs 
 
It is well known that inotropes may improve haemodynamics and help reverse worsening end‐organ 
function in advanced heart failure (Table 7). However, inotropes studied in randomized clinical trials 
have generally not been associated with improved outcomes, and have, in some studies, worsened 
prognosis.
147-149
 Hence, inotropes have no place in the routine treatment of advanced heart failure. 
However, there is expert opinion that inotropic support may be necessary in refractory heart failure in 
selected patients as a bridge to temporary MCS, long‐term MCS, or heart transplantation. Inotropes may 
also be used as short‐term therapy in patients with low cardiac output and evidence of end‐organ 
dysfunction, for instance during decongestion. Long‐term (i.e. months) or chronic treatment after 
discharge with inotropes for patients waiting for transplantation, is not routinely recommended. These 
patients should probably be considered for long‐term MCS if feasible.150, 151 However, patient preferences 
regarding inotropic therapy or MCS for patients awaiting transplantation should be assessed. Continuous 
inotropes may be acceptable as a palliative measure for patients without other advanced treatment 
options.  
  
Table 7. Inotropes and vasoconstrictors 
 
Mechanism of action Haemodynamic effect Comment 
    
Inodilators    
Dobutamine Beta‐1 activation, slight beta‐2 vasodilatation CO ↑, SVR ↓ Half‐life minutes 
Milrinone PDE2 inhibition CO ↑, SVR ↓ Half‐life 2 h 
Levosimendan Calcium sensitization CO ↑, SVR ↓ Half‐life (metabolite) days 
Inotropes/vasoconstrictors    
Dopamine Beta‐1, alpha‐adrenergic, and dopaminergic 
activation 
CO ↑, SVR ↑ 2–10 µg/kg/min: beta‐1 
>10 µg/kg/min: alpha, beta‐
1 
Adrenaline Beta‐1, alpha‐adrenergic, moderate beta‐2 
activation 
CO ↑, SVR ↑  
Vasoconstrictors    
Norepinephrine Beta‐1, alpha activation SVR ↑, CO ↔/↓  
Vasopressin V1 and V2 activation SVR ↑, CO ↔/↓  
    
 
CO, cardiac output; PDE2, phosphodiesterase‐2; SVR, systemic vascular resistance. 
 
Vasopressors (dopamine, norepinephrine, epinephrine) are broadly associated with worse outcomes in 
observational studies,
152
 and low‐dose dopamine does not improve congestion or cardiovascular outcomes 
compared to placebo in acute decompensated heart failure.
153, 154
 Hence, these agents should be reserved 
for patients with low systolic blood pressure and evidence of organ hypoperfusion (cardiogenic shock) at 
the lowest dose that obtains the desired clinical goals, and only if the low blood pressure is considered a 
reversible condition or definitive therapy (long‐term MCS or transplantation) is planned.  
 
Intermittent use of inodilators for long‐term symptomatic improvement or palliation has gained 
popularity, especially use of levosimendan, since the haemodynamic effect may last for >7 days after a 
12–24 h infusion because of the pharmacologically active metabolite with a long half‐life.155 While meta‐
analyses of several heterogeneous small trials of a repeated infusion strategy have suggested a positive 
effect on survival
156 
and a reduction in hospitalizations,
157
 such a survival effect has not been 
demonstrated in a single, adequately sized, prospective study. The LION‐HEART pilot study randomized 
69 patients with advanced heart failure to placebo or levosimendan 0.2 µg/kg/min over 6 h every 2 weeks 
for 12 weeks.
158
 NT‐proBNP over time, the primary endpoint, was significantly lower in the 
levosimendan group compared to the placebo group. Patients randomized to levosimendan were also less 
likely to be hospitalized for heart failure or experience a decline in health‐related quality of life compared 
to placebo. Adverse events were similar between groups.
158
 More studies are needed to determine if this 
approach may be useful for patients with contraindications to transplantation or long‐term MCS.  
 
Whether or not to implant an implantable cardioverter‐defibrillator (ICD) in patients listed for heart 
transplantation is still a matter of debate. This decision is usually made on an individualized basis, 
balancing the expected risks of sudden death and device‐related complications, and considering the 
expected waiting time for transplantation. In the absence of randomized trials, the best evidence regarding 
this controversial topic comes from a Swiss observational study,
159
 in which a significant survival benefit 
was observed for ICD carriers, both as primary or secondary prevention, with a median waiting list time 
for transplantation of only 8 months. In recent years, wearable defibrillators have emerged as a potential 
effective and less invasive alternative to conventional implantable devices for this purpose.
160 
  
Management of congestion 
 
Most of the heart failure hospitalizations are due to signs and symptoms of fluid overload.
161
 
Recurrent congestion worsens patients' outcomes. Loop diuretics remain the cornerstone for the treatment 
of congestion in the patients with heart failure. Diuretic therapy is thoroughly described in the current 
guidelines for heart failure treatment and their further discussion goes beyond the aims of this article. The 
clinical course of patients with advanced heart failure is often characterized by kidney dysfunction 
(cardiorenal syndrome) and by diuretic resistance. The first may have multiple mechanisms including 
abnormal haemodynamics, neurohormonal activation, excessive tubular sodium reabsorption, 
inflammation, oxidative stress, and nephrotoxic drugs.
161
 Loop diuretic resistance is generally due to a 
series of renal adaptations after diuretic use (‘braking phenomenon’) including hypertrophy and 
hyperfunction of other sites of the nephron and to increased renin secretion in the macula densa. Increased 
uremic anions and proteinuria also impair achievement of therapeutic concentrations at the diuretic's 




Concomitant administration of thiazide diuretics or metolazone with loop diuretics is used to 
overcome the braking phenomenon. However, no evidence from clinical trials exists to guide this 
practice. Ultrafiltration (UF) might be an alternative to loop diuretic administration. It removes isotonic 
fluid without direct activation of the renin–angiotensin–aldosterone system, if fluid removal rates do not 
exceed capillary refill. Greater access to UF stems from the development of simplified devices not 




The adjustment of UF rates to patients' vital signs and renal function may provide more effective 
decongestion and fewer heart failure events than standard of care.
161
 The results of UF studies are 
summarized in the online supplementary Table S1.  
 
Practice guidelines suggest that patients with an inadequate response to oral diuretic treatment should 
receive intravenous diuretics starting with an intravenous dose greater than that of the oral treatment. The 
initial dose of the intravenous treatment should be increased in case of an inadequate response.
6, 9
 
Persistent congestion can then be treated by adding thiazide, or thiazide‐like, diuretic agents, aldosterone 
antagonists. Only if these measures fail can UF be considered.
6, 9
 However, favourable results of trials of 
early UF underscore the need for additional investigation of UF in clinical settings as an alternative to 
high‐dose diuretic treatment.163, 164 
 
Once an initial UF rate is chosen, it should be either maintained or reduced because capillary refill 
from the interstitium decreases as fluid is removed.
165
 Rates of UF >250 mL/h are not recommended.
164 
Patients with right‐sided heart failure or HFpEF are susceptible to intravascular volume depletion and 
may only tolerate low UF rates (50 to 100 mL/h).
164
 Extracorporeal fluid removal is better tolerated when 
conducted with low UF rates delivered over several hours. Patients' current weight can be compared with 
that preceding the signs and symptoms of congestion and used as the target for fluid removal.
164 
Inline 
haematocrit sensors permit continuous estimation of blood volume changes during UF and can be 
programmed to stop fluid removal if the haematocrit exceeds a set threshold (e.g. 5% to 7%) and resume 
therapy when the haematocrit value falls below the pre‐specified level, indicating an adequate 
intravascular volume. Bioimpedance vector analysis, bioimpedance spectroscopy, electromagnetic 
technology and pulmonary artery pressure sensors all have limitations for estimation of blood volume and 




The Peripheral Ultrafiltration for the Relief from Congestion in Heart Failure (PURE‐HF) trial 
(NCT03161158) will evaluate whether peripheral UF combined with low‐dose intravenous diuretics 
result in fewer heart failure events and cardiovascular deaths at 90 days compared to guideline‐directed 
therapy including intravenous diuretics in patients with heart failure hospitalized for congestion. 
 
Peritoneal dialysis is a home‐based therapeutic modality than can be used in patients with refractory 
heart failure, cardiorenal syndrome and fluid overload. The peritoneum is used as the filter through which 
solute molecules can be exchanged between the dialysate (delivered to the peritoneal cavity through a 
catheter) and the blood.
166
 With peritoneal dialysis, removal of sodium and water by UF occurs because 
of the osmotic pressure gradient between the hypertonic dialysate and the hypotonic peritoneal capillary 
blood. Peritoneal dialysis has a role in patients with concomitant heart failure with and without advanced 
CKD (Stages IV/V) in whom peritoneal dialysis is used as an UF strategy and those with heart failure and 
end‐stage renal disease in whom peritoneal dialysis is the renal replacement therapy of choice (CKD 
Stage V). Studies of peritoneal dialysis in heart failure patients with CKD and refractory fluid overload 
have shown this modality is associated with weight loss, improved quality of life, and reduction in heart 
failure hospitalizations and increase in LVEF.
167-170 
However, these studies lack a control group, have a 
short follow‐up, and insufficient power to detect an effect on mortality.  
 
During the first 60–90 min of intraperitoneal dwell of dextrose‐containing peritoneal dialysis 
solutions, rapid transport of free water across the aquaporin channels occurs, whereas the solute‐rich 
water moves more slowly through the small pores of the peritoneal membrane. This results in an early 
drop in the concentration of sodium in the dialysate. This approaches the serum concentration as the 
diffusive movement of sodium continues and dwell time is sufficiently long.
166 
The longer dwells of 
continuous ambulatory peritoneal dialysis may be preferred when sodium removal is the primary target, 
as it is in fluid‐overloaded patients with heart failure.170 Several strategies allow adequate sodium and 
water removal with automated peritoneal dialysis.
169
 One approach is to substitute conventional dextrose‐
based dialysis solutions with icodextrin, a high molecular weight glucose polymer which induces 
transcapillary UF.
171
 Another strategy is to decrease the number of nocturnal cycles to increase the dwell 
time. For patients with significant residual renal function, dietary sodium restriction and concomitant use 
of loop diuretics may enhance sodium removal by peritoneal dialysis.
172
 Future studies should determine 
if peritoneal dialysis is associated with improved survival.  
Short‐term mechanical circulatory support 
 
Among patients with advanced heart failure, short‐term MCS may be indicated in the setting of 
cardiogenic shock. Several percutaneous and paracorporeal devices are available which can be used for a 
few days, up to several weeks, to allow cardiac recovery as well as recovery of other organs such as the 
kidneys, liver, and brain. Although insertion of most short‐term devices is relatively simple and 
straightforward, the care of patients on short‐term MCS requires specific expertise which should also 
include a plan when cardiac recovery does not occur after a period of support. In this way, short‐term 
MCS can be used as a bridge‐to‐decision (BTD) for long‐term MCS or heart transplantation.173 As there 




Intra‐aortic balloon pump 
 
An intra‐aortic balloon pump (IABP) consists of a percutaneously implanted catheter with a balloon 
inflated with gas (usually helium, a low‐density gas) that is positioned in the aorta between the left 
subclavian artery and the renal arteries. Intra‐aortic balloon pumps have been used clinically for more 
than five decades. The mechanism of action is based on the principle of diastolic augmentation, i.e. the 
balloon is inflated during diastole and deflated during systole, thus facilitating coronary flow and 
improving oxygen supply to the myocardium and reducing afterload, thus reducing oxygen consumption. 
Its contribution to cardiac output is small, merely 0.5 L/min by some approximations. A small (n=10) 
study reported a median increase of 20% in cardiac index and significant reductions in left ventricular 
stroke work and left ventricular end‐systolic pressure in patients undergoing IABP support before LVAD 
implantation.
175
 Currently, IABP are primarily used for cardiogenic shock in the setting of acute 
ischaemic heart disease, and for protective support during high‐risk percutaneous coronary intervention, 
but scientific evidence for these applications is lacking.
176, 177
 Intra‐aortic balloon pumps are sometimes 
used to provide mechanical support to patients with cardiogenic shock prior to LVAD implantation, but 
the evidence for this practice is also limited. A small single‐centre study (n=56) reported that IABP 
provided clinical stabilization in 57% of the patients who received IABP prior to LVAD implantation, 
whereas the remaining 43% had further clinical deterioration.
178
 Higher right ventricular and left 
ventricular cardiac power indices and higher pulmonary artery pressure may predict patients more likely 
to respond to IABP.
178
 In general, newer devices that generate greater support and provide better 
unloading of the left ventricle are currently preferred.  
  
Extracorporeal membrane oxygenation 
 
Extracorporeal membrane oxygenation (ECMO) is a cardiopulmonary bypass machine modified for 
easier and longer use and transport. Extracorporeal membrane oxygenation devices have a centrifugal 
blood pump that can provide up to 6 L/min of flow, as well as an oxygenator to provide full respiratory 
support. Thus, ECMO provides full systemic circulatory support and can be useful to restore end‐organ 
perfusion. 
 
Extracorporeal membrane oxygenation can be used in either veno–arterial or veno–venous 
configurations. The veno–arterial mode provides full cardiopulmonary support, while the veno–venous 
mode provides only respiratory support, i.e. oxygenation of venous blood, and it is used primarily in cases 
of severe respiratory insufficiency with preserved cardiac output. Extracorporeal membrane oxygenation 
can be configured with central or peripheral access. Central ECMO requires surgical access and 
cannulation of the ascending aorta, and it is predominantly used for postcardiotomy short‐term MCS in 
patients who fail to wean off cardiopulmonary bypass. Conversely, peripheral ECMO can be placed by 
interventional cardiologists or trained intensivists using the Seldinger technique for insertion of cannulas 
in the femoral artery and vein. 
 
Implantation and management of ECMO demands a dedicated team with expertise in this specific 
area. Perfusion technicians are essential for ECMO circuit priming and initiation; transoesophageal 
echocardiography or fluoroscopic guidance is advisable for cannula positioning, and vascular or cardiac 
surgeons must be available to manage possible vascular complications. Extracorporeal membrane 
oxygenation support demands anticoagulation with heparin; activated clotting time should be monitored 
frequently and maintained between 160–180 s. Complications of ECMO support are frequent and are 
mostly related to vascular complications, bleeding, thrombosis, and infections. In the case of peripheral 
ECMO, distal limb ischaemia remains relatively frequent despite the routine addition of a cannula for 
distal limb perfusion. 
 
Although ECMO provides full support for the patient, it may have non‐physiologic and sometimes 
detrimental haemodynamic consequences on the myocardium. Draining blood from the venous side 
results in a reduction of preload to the heart, and, consequently, reduces filling pressures of both 
ventricles. On the arterial side, ECMO delivers 4–6 L/min of flow to the aorta resulting in increased 
afterload to the left ventricle. Therefore, ECMO in itself does not necessarily decompress the heart, and 
depending on the severity of myocardial dysfunction and presence of aortic or mitral regurgitation, 
peripheral femoro–femoral ECMO may even increase left ventricular end‐diastolic pressures and 
volumes. The resulting pulmonary venous congestion may lead to pulmonary oedema and compromise 
respiratory function.179 In these cases, a few modifications in the ECMO circuit can be performed to 
optimize support, such as inserting a left atrial vent for unloading the pulmonary veins/left atrium (e.g. 
with central ECMO) or the left ventricular apex (e.g. with peripheral ECMO), or adding a second device 
to unload the left ventricle [e.g. IABP, Impella Ventricular Support Systems (Abiomed Inc., Danvers, 
MA, USA), or other short‐ to‐medium‐term surgically implanted MCS device].180, 181 Percutaneous left 
atrial septostomy has also been reported as a method to unload the left heart in ECMO‐supported patients 
with refractory pulmonary oedema.
182 
Native cardiac output and ECMO flow should be carefully 
balanced to prevent hypoxic blood perfusing the brain and the well‐oxygenated blood mainly perfusing 
the rest of the body. Absence of native cardiac output may even result in complete clotting of the left 
ventricle despite adequate heparin treatment. ECMO can readily be used in cardiogenic shock caused by 
end‐stage chronic heart failure as a short‐term bridge‐to‐transplantation (BTT), BTD, or bridge‐to‐
candidacy (BTC).
180, 181
 The SAVE score (www.save‐score.com) can be used as a tool to predict survival 
in patients with cardiogenic shock in which ECMO is considered.
183 
ECMO has been registered for use up 
to 30 days.  
 
A recent meta‐analysis of cohort studies suggested better survival rates and neurological outcomes in 
cardiac arrest patients when treated with ECMO in comparison to controls in whom ECMO was not 
used.
184 
Furthermore, ECMO provided better survival in patients in cardiogenic shock when compared to 
IABP. The same effect was not observed when ECMO was compared to Impella or TandemHeart.
185 
  
TandemHeart® percutaneous ventricular assist device (Cardiac Assist, Inc., Pittsburgh, PA, USA) 
 
TandemHeart is a device that connects the left atrium with the iliofemoral artery.
186, 187
 TandemHeart 
consists of a 21 Fr inflow cannula (inserted via the femoral vein to the right atrium and trans‐septally into 
the left atrium), a centrifugal continuous extracorporeal blood pump, and an outflow arterial cannula (15‐
19 Fr, inserted in the iliofemoral artery). A membrane oxygenator can be added to the TandemHeart 
circuit to provide respiratory support. TandemHeart has Food and Drug Administration (FDA) approval 
for 6 h of support and also CE mark, which includes approval for Protec Duo veno–venous cannula up to 
30 days (www.tandemlife.com).  
 
The need for trans‐septal puncture and positioning of the inflow cannula into the left atrium demands 
proficiency in its use. This makes the implant procedure more complex and longer as compared to other 
short‐term percutaneously implanted devices. 
 
The main advantages of this device are the direct unloading of the left atrium which results in a 
decrease in left ventricular filling pressures, volumes and oxygen demand and that it does not require 
passage into the left ventricle. However, positioning of the cannula in the left atrium carries a risk of 
complications, such as perforation, or most frequently, cannula migration to a suboptimal position or back 
to the right atrium. Furthermore, pumping blood out of the left atrium depends on preload to the left 





Other contraindications include significant peripheral vascular disease, general contraindications for 
anticoagulation therapy, presence of right or left atrial thrombi, ventricular septal defect, or severe aortic 
insufficiency. Anticoagulation therapy is mandatory due to the high risk of thromboembolic events. 
Requirements for activated clotting time are even higher than for ECMO, and should be around 300 s, 
which significantly increases the risk of bleeding complications. 
 
Other important complications of TandemHeart support are vascular site complications, infections, 
and thromboembolic incidents. The major disadvantage is the immobility of the supported patient; care 
providers must secure the inflow cannula since movement of the tip from the left to right atrium results in 
significant right‐to‐left shunting with catastrophic desaturation. 
 
TandemHeart improves haemodynamics by adding up to 4 L/min of cardiac output and lowering 
pulmonary capillary wedge pressure. However, a positive effect on survival has not been established in 
studies performed to date.
189, 190
 
Impella® ventricular support systems (Abiomed Inc., Danvers, MA, USA) 
 
The Impella device is a small axial flow pump placed across the aortic valve, aspirating blood from 
the left ventricle and expelling it to the ascending aorta. In this way, it unloads the left ventricle, 
improving haemodynamics combined with decreasing pulmonary capillary wedge pressure, and 
increasing coronary artery flow. Contraindications include severe aortic valve disease (both stenosis and 
regurgitation), implanted mechanical aortic valve, or existence of left ventricular thrombus. Impella is 
manufactured in three versions: 2.5 device (12 Fr, maximum flow 2.5 L/min), CP device (14 Fr, 
maximum flow 2–4 L/min), and 5.0 device (21 Fr, maximum flow 5 L/min). Impella 5.0 is not fully 
percutaneous and requires a surgical procedure to insert a 21 Fr catheter in the femoral artery. Preliminary 




The distal tip of the catheter is designed as a pigtail catheter which contributes to stability in the left 
ventricular cavity and reduces suction events. Survival benefit with the 2.5 device in cardiogenic shock 
could not be demonstrated, and it is generally advised to use either the CP device or the 5.0 device in such 
cases.
192
 Recent results suggest that when used as part of a standardized protocol in patients with 
cardiogenic shock and isolated left ventricular failure, early active haemodynamic support with Impella 





The Impella device is FDA approved for partial support of up to 6 days, and it has a CE mark for up to 
5 days. As with all peripheral percutaneous devices, peripheral artery disease is a contraindication to its 
use, as well as the inability to anticoagulate patients for any reason. Major complications of Impella use 
are associated with vascular injury, bleeding, thrombosis, haemolysis, and device migration. Recently, 




CentriMag acute circulatory support system (St. Jude, Minneapolis, MN, USA) 
 
The CentriMag is a magnetically levitated paracorporeal centrifugal pump which can be used for left 
ventricular, right ventricular, and biventricular support. It requires surgical implantation by way of 
sternotomy but results in full circulatory support and complete cardiac unloading. Maximal flow is 
10 L/min and duration of support is intended for up to 30 days, but longer is possible. It requires 
anticoagulation with intravenous heparin. This device can be used as a bridge‐to‐recovery or as a BTD for 
those patients who need a longer duration of support than is feasible by the previous mentioned devices. 
Also, the possibility of right ventricular support can be an advantage.
195, 196
 A new approach, minimally 
invasive CentriMag support integrated with ECMO (Ec‐VAD) not requiring a sternotomy has been 
reported.
197 
The Ec‐VAD circuit is configured with left ventricular apical cannulation via mini‐
thoracotomy and femoral venous cannulation as inflows and right axillary artery cannulation as an 
outflow.  
Long‐term management of advanced heart failure 
Advanced heart failure therapies are indicated when guideline‐directed medical and device therapies 
have been implemented and optimized as appropriate in the individual patient but heart failure has 
progressed such that symptoms can no longer be adequately managed or end‐organ function is 
compromised. Although details on guideline‐directed medical and device therapies for chronic heart 
failure are not described herein, physicians should refer to existing guideline documents9 to ensure 
optimization prior to considering advanced heart failure therapies, and for guidance on the continued 
management of these patients.  
Conventional cardiac surgery 
 
For patients with an LVEF ≤35% and coronary artery disease amenable to surgical revascularization, 
coronary artery bypass grafting in addition to medical therapy significantly reduced the primary outcome 
of all‐cause death, and the secondary outcomes of cardiovascular death and all‐cause death or 
cardiovascular hospitalization compared to medical therapy alone over 10 years of follow‐up in the 
Surgical Treatment for Ischemic Heart Failure (STICH) trial.
198, 199
 Coronary artery bypass graft surgery 
is recommended for such patients with left main stenosis or left main equivalent.
200
 For patients with 
unacceptably high surgical risk, coronary intervention is an option and may be facilitated under protection 




In severe symptomatic aortic valve stenosis with mean gradient >40 mmHg, aortic valve replacement 
(AVR) is recommended irrespective of the degree of left ventricular dysfunction. In patients with 
prohibitive surgical risk due to co‐morbidities but with projected survival >1 year after aortic valve 
intervention, transcatheter aortic valve implantation should be considered. In ‘true’ low‐flow, low‐
gradient severe aortic stenosis
202
 (valve area <1 cm
2
, mean gradient <40 mmHg, stroke volume index <35 
mL/m
2
), with a depressed LVEF, left ventricular function usually improves after AVR if left ventricular 
dysfunction is due to excessive afterload; however, outcome is less certain if left ventricular dysfunction 
is due to scarring. In severe aortic regurgitation, AVR is recommended in all symptomatic patients as well 
as asymptomatic patients with LVEF ≤50%.
202
 According to the most recent valvular guidelines, ‘in 
patients with severe secondary mitral regurgitation and LVEF <30% who remain symptomatic despite 
optimal medical management (including CRT if indicated) and who have no option for revascularization, 
the Heart Team may consider a percutaneous edge‐to‐edge procedure or valve surgery after careful 
evaluation for a ventricular assist device or heart transplant according to individual patient 
characteristics.’
202
 Additionally, ‘in patients with LVEF <30% and severe functional mitral regurgitation 
due to coronary artery disease, but with evidence of myocardial viability, mitral valve surgery should be 
considered with revascularization.’
202
 However, there is a legitimate concern that the more advanced the 
heart failure stage, the less likely that a mitral repair operation or clip procedure can benefit the patient. 
The ongoing COAPT (Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for 
Heart Failure Patients with Functional Mitral Regurgitation, NCT01626079) will evaluate the safety of 





Heart transplantation is the treatment of choice for carefully selected patients with advanced or end‐
stage heart failure. Although controlled trials have never been conducted, there is consensus within the 
cardiology community that heart transplantation significantly improves survival, exercise capacity, 
quality of life and return to work compared with conventional treatment, provided that proper selection 
criteria are applied (Table 8).
9, 25
 The main limitation of heart transplantation is the limited supply of 
donor hearts, which can vary substantially by country. Availability may impact indications and 
contraindications for heart transplant applied locally.  




1. End‐stage HF with severe symptoms, a poor prognosis, and no remaining alternative treatment 
options 
2. Motivated, well informed, and emotionally stable 
3. Capable of complying with the intensive treatment required postoperatively 
Contraindications 1. Active infection 
2. Severe peripheral arterial or cerebrovascular disease 
3. Pharmacologic irreversible pulmonary hypertension (LVAD should be considered with subsequent 
re‐evaluation to establish candidacy) 
4. Cancer (a collaboration with oncology specialists should occur to stratify each patient as to their risk 
of tumour recurrence) 
5. Irreversible renal dysfunction (e.g. creatinine clearance <30 mL/min) 
6. Systemic disease with multiorgan involvement 
7. Other serious co‐morbidity with poor prognosis 
8. Pre‐transplant BMI >35 kg/m2 (weight loss is recommended to achieve a BMI <35 kg/m2)  
9. Current alcohol or drug abuse 




BMI, body mass index; HF, heart failure; LVAD, left ventricular assist device. 
Adapted from Ponikowski et al.9 and Mehra et al.25 
Since the first case of human heart transplant in 1967,
203
 post‐transplant survival has improved 
because of developments in recipient and donor selection, immunosuppression, and management of 
infectious complications. Thus, heart transplantation is now considered the gold standard therapy for 
refractory heart failure. Data from the latest International Society for Heart and Lung Transplantation 
(ISHLT) Registry shows 1‐year survival of around 90% and median survival of 12.2 years.19 
Transplantation not only improves survival but also functional status and quality of life. At 1 to 3 years 
post‐cardiac transplant, the proportion of survivors capable of normal activity (defined as physician‐rated 
Karnofsky score 80–100%) is 90%.
204
 The main challenges after heart transplantation are the 
consequences of both limited effectiveness and complications of immunosuppressive therapy (e.g. 
infections, antibody‐mediated rejection, cardiac allograft vasculopathy, late graft dysfunction, 
malignancy, renal dysfunction, hypertension, diabetes mellitus).
204 
 
The patient evaluation before listing for transplant involves four main considerations. First, the 
presence of refractory heart failure should be confirmed to ensure that there are no other treatable 
aetiologies or alternative explanations for advanced symptoms. This step is important to guarantee the 
patient's candidacy for cardiac transplant and to reserve scarce donor organs for patients with the greatest 
need. Second, prognosis should be estimated. The greatest survival benefit is achieved in patients with a 
high mortality risk without heart transplant that also have a good expected survival post‐transplant.205 
Third, co‐morbidities should be evaluated to detect conditions that may negatively affect surgical and/or 
post‐transplant outcomes or require special management.25, 204 Diagnostic and other tests [e.g. complete 
medical history, physical examination, CPET,
25, 88 
right heart catheterization, evaluation of peripheral 
vascular disease, assessment of frailty and nutritional status,
206
 determination of organ function (lung, 
liver and kidney), screening for neoplasms or active infections],
25







), and other studies as indicated based on co‐morbidities (Table 9)208-213 are used to 
assess these three components of the pre‐cardiac transplant evaluation. Other health maintenance 
assessments should be performed (e.g. vaccination status) and addressed as clinically indicated. Blood 
group compatibility is mandatory for adult heart transplant patients. HLA antibody assessment is 
recommended; however, there is no consensus regarding the level and type of antibodies that 
contraindicate a specific donor.
214 
Finally, a complete psychosocial evaluation should be included in the 
evaluation of all heart transplant candidates during the initial screening process to identify social and 
behavioural factors that may cause difficulties during the waiting period, convalescence, and long‐term 
follow‐up, particularly regarding substance abuse, adherence to therapy and follow‐up visits.213 Assessing 
that the patient has adequate social support (i.e. family or friends able to give support and who are willing 
to make long‐term commitments for the patient's welfare) is also a critical component.215 An important 
aspect of the pre‐transplant cardiac evaluation is the identification of those patients who do not yet need a 
heart transplant and should either not be listed or removed if already listed with close monitoring and 
follow‐up.  
Table 9. Considerations in assessment of co‐morbidities 
  
Co‐morbidity Parameters to evaluate 
Age208 Frailty 
Co‐morbidity burden 
Local organ availability and quality 
Obesity Body mass index 
Diabetes mellitus End‐organ damage (e.g. neuropathy, nephropathy) 
Glycated haemoglobin 
Renal impairment Estimated GFR 
Renal ultrasonography 
Proteinuria estimation 
Presence of renal arterial disease 
Candidacy for combined heart/kidney transplant209 
Cancer Active malignancy 
Collaboration with oncologist for prior cancer previously treated 
Previous tumour type, response to therapy 
Metastatic work‐up 
Cerebral or peripheral vascular disease Diagnostic work‐up as indicated to assess clinical severity 
Potential to limit rehabilitation 
Substance abuse Tobacco (including environmental or second‐hand exposure) 
Alcohol 
Recreational drugs 
HIV210, 211 Active or prior opportunistic infections 
Adherence to combination anti‐retroviral therapy 
HIV RNA 
CD4 count 
Chagas disease212 Serology testing for T. cruzi in patients at risk  
Hepatitis B and C Antibody/antigen testing 
HCV RNA PCR 




Psychosocial Complete evaluation 
Potential for adherence to therapy213 
  
 
CD4, cluster of differentiation 4; GFR, glomerular filtration rate; HCV, hepatitis C virus; HIV, human immunodeficiency virus; 
PCR, polymerase chain reaction; RNA ribonucleic acid. 
Some aetiologies of advanced heart failure (e.g. hypertrophic cardiomyopathy, restrictive 
cardiomyopathy, arrhythmogenic right ventricular dysplasia, complex congenital heart disease, and 
infiltrative cardiomyopathies) require specific approaches to diagnosis, prognosis, and determination of 
transplant eligibility, as described elsewhere.
25
 Patients with restrictive cardiomyopathy and severe heart 
failure symptoms may be candidates for cardiac transplantation. Collaboration with other specialties is 
necessary to manage other organ systems impacted by these diseases. For example, in addition to heart 
transplantation, a hepatic transplant may be required for familial amyloidosis related to mutations in the 
transthyretin gene, or an autologous stem cell transplantation may be indicated for light chain 
amyloidosis.
25
 Special considerations are needed for patients with congenital heart disease and in 
recipients that harbour chronic infections (e.g. Chagas disease, tuberculosis, human immunodeficiency 





Pre‐operative clinical stability is a strong predictor of early post‐transplant outcomes; however, 
clinical instability can also be a priority criterion in some countries for organ allocation. Mechanical 
circulatory support systems can bridge selected patients to transplantation who are extremely ill and have 
a high‐expected mortality while awaiting a suitable donor heart. Short‐term MCS can also serve as a 
bridge in patients initially ineligible for transplantation, such as those in cardiogenic shock with end‐
organ damage. In these cases, short‐term MCS may stabilize haemodynamics and end‐organ perfusion 
and permit an evaluation of candidacy (e.g. determine extent of brain damage or other end‐organ injury 
post‐resuscitation).9,173 Although urgent cardiac transplant listing is possible in many countries, the 
appropriateness of this strategy is now being debated. Among patients listed for emergent cardiac 
transplant in the Spanish National Heart Transplant Registry database, recipients meeting the 
INTERMACS profile 1 criteria (cardiogenic shock) and profile 2 criteria (progressive clinical decline 
despite treatment with inotropes) had the highest risk of primary graft failure, dialysis requirement, and 
in‐hospital mortality following heart transplantation.216 Therefore, in these critically ill patients, short‐
term MCS as a BTD might constitute a more reasonable initial strategy than an urgent transplant.  
Long‐term mechanical circulatory support 
 
Long‐term support with durable MCS devices like LVAD in patients with advanced heart failure has 
survival benefits and improves quality of life compared with conventional treatments in inotrope‐
dependent patients or in patients with contraindications for heart transplantation.
9
 The Randomized 
Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure (REMATCH) trial 
first showed improved 1‐year survival in inotrope‐dependent, transplant‐ineligible patients with advanced 
heart failure treated with an LVAD, but 2‐year survival was not statistically different.217 Since then, 
technology of LVAD and conservative management have improved.
217, 218
 Managing patients with long‐
term MCS requires a multidisciplinary Heart Team approach, and by gaining experience, centres may 




Originally considered only as a lifesaving therapy for patients who were ineligible for heart 
transplantation, the proportion of long‐term MCS devices implanted for destination therapy (DT) to heart 
transplants is increasing.
220
 This growth is due to a growing shortage of donor hearts, increasing numbers 
of advanced heart failure patients, and continuous improvements in MCS technologies and survival rates.  
Patient selection for long‐term durable mechanical circulatory support 
 
The INTERMACS profiles can help identify potential candidates for MCS
221
 (Table 2). INTERMACS 
profile 1 indicates critical cardiogenic shock with very limited time for decision and intervention. 
Similarly, INTERMACS profile 2 indicates progressive decline despite inotropic support. In these 
patients, many centres prefer to use either paracorporeal or percutaneous short‐term assist devices as a 
BTD. Long‐term MCS devices are also an option for these patients. INTERMACS 3 patients are those 
who are stable on inotropes and are optimal candidates for implantable MCS, as their outcomes are 
significantly better than patients categorized as INTERMACS 1 or 2, and the potential for benefit 
overwhelms the risks of complications. Data from selected retrospective studies showed that survival 
rates were even better in non‐inotrope dependent NYHA class IV patients or advanced NYHA class III 
patients (INTERMACS profiles 4–7).
151, 222, 223
 A prospective, non‐randomized, observational, propensity‐
adjusted study comparing LVAD with optimal medical management showed that a greater proportion of 
patients treated with LVAD survived for 12 months and had improvement in 6‐min walk distance, along 





Although INTERMACS profiles alone are insufficient to evaluate an individual patient for MCS, 
based on available data selected INTERMACS 1–2 patients and all INTERMACS 3 patients should be 
considered for MCS. Furthermore, carefully selected INTERMACS 4–7 patients who are willing to 
accept a risk of adverse events in exchange for potentially longer survival and better functional status can 
be considered for MCS.
104, 151, 224
 In addition to INTERMACS profiles 1–2, risk factors for early mortality 
after MCS system implantation include renal dysfunction, elevated bilirubin, advanced age, female 




Patient selection for MCS overlaps with indications for heart transplantation.
25
 However, as heart 
transplantation is still the gold standard, the use of LVAD therapy should be projected in light of the 
possibility to offer transplant opportunity to the patient, and it would be advisable that 
indications/contraindications to transplant are ruled out by the transplant centre before a device is 
implanted. Based on this concept, LVADs may be implanted according to three major treatment 
strategies: BTT, BTC and DT. In rare circumstances, LVAD therapy may lead to a recovery of heart 
function (bridge to recovery). In this context, however, in countries with low or declining transplant rates, 
implanting an LVAD as a BTT usually becomes DT, unless pump‐related complications occur such as 
chronic driveline infection, bleeding, or thrombosis.  
 
High pulmonary vascular resistance or transpulmonary gradient, or a recently treated cancer are 
contraindications for heart transplantation but not for MCS. On the other hand, severe right ventricular 
dysfunction
228
 is a contraindication for LVAD, because there are still no good long‐term solutions for 
right ventricular or biventricular mechanical support. Severe renal insufficiency is a contraindication for 
heart transplantation, but renal or liver function may improve after MCS,
229 
as may pulmonary vascular 
resistance.
230
 Thus, with the exception of advanced age or other irreversible contraindications for 
transplant, MCS should primarily be considered as BTC rather than DT. However, some patients with 




In general, early referral of patients with advanced heart failure to transplant and MCS centres can 
assure the best timing and outcomes for both transplantation or long‐term MCS. Early referral applies to a 
wide spectrum of patients ranging from housebound NYHA class IV patients with poor exercise capacity 
despite optimal medical treatment plus CRT if needed, to NYHA class IV patients who are refractory to 
conventional treatments. Shared decision making is an important component of determining the 
appropriateness of long‐term MCS.232 
Adverse events and morbidities related to mechanical circulatory support 
 
MCS‐specific infections may be on the hardware itself or the body surfaces that contain them and 
include infections of the pump, cannula, anastomoses, pocket, or the percutaneous driveline or tunnel.
233
 
Driveline exit site infection is a common complication, occurring in 20–25% of patients (data from main 
randomized clinical trials),
234, 235
 but the majority remain superficial and can be managed by antibiotics.
236
 
Exit site swabs and blood cultures are obligatory when driveline infection is suspected. Resistant and 
complicated driveline infections (i.e. ascending driveline or pump pocket infection) can be an indication 
for listing the patient for urgent heart transplantation if there are no contraindications.
224
 The ISHLT 
standardized definitions for MCS infections to differentiate ventricular assist device (VAD)‐specific 
infections, VAD‐related infections, and non‐VAD infections.233 Driveline infection can be further 
classified into superficial and deep according to surgical/histology, microbiology, and clinical criteria as 
well as general wound appearance.  
 
Other complications include heart failure symptoms on MCS, which may be attributed to device 
failure, mechanical issues, or cannula malposition. Right ventricular dysfunction, new onset of right heart 




Treatment with anticoagulation and antiplatelet agents are mandatory to minimize the risk for pump 
thrombosis. Both embolic ischaemic events and bleeding events secondary to these therapies remain 
major complications of MCS and contribute to readmission and death.
237
 Continuous flow devices have 
raised important considerations for haemocompatibility
.237
 Routine monitoring of plasma‐free 
haemoglobin and lactate dehydrogenase as haemolysis markers are useful for early detection of pump 
thrombosis. In HeartWare HVAD carriers, routine log‐file review has demonstrated its usefulness for the 
early detection of pump thrombosis. In case of clinical suspicion, the diagnosis of pump thrombosis may 





Currently, there are several vendors and a considerable number of devices that are used for medium‐
term and long‐term MCS. Continuous flow implantable MCS devices of the second and third generation 
have shown significant superiority over pulsatile first‐generation implantable MCS devices. Thus, in the 
last 15 years, the landscape of potential options in MCS has changed dramatically. Currently, the three 
MCS devices most often used are the HeartMate II, HeartWare HVAD, and HeartMate 3 (Table 10).
151, 
223, 234, 235, 239-258
 These devices have shown good durability, reasonable but still relatively high rates of 
device‐related morbidity, improved functional capacity in implanted patients, and in the case of 
HeartMate 3, mid‐term survival rates approaching that of post‐transplant survival (overall 2‐year survival 
of 83%). The incidence of adverse events with recent technological improvements (e.g. as with the fully 
magnetically‐levitated HeartMate 3 potentially almost eliminating pump thrombosis) has reduced the 
rates of reoperation to replacement or removal a malfunctioning device, and disabling strokes, although 
the incidence of other adverse events is similar between newer and older devices.
258
 Particular concern 
exists with stroke rates, especially with the HVAD device (29% at 2 years), and the HeartMate 3 has 
demonstrated a halving of stroke rates at 2 years compared to the HeartMate II device.
258
 Minimally 
invasive VAD implantation methods will hopefully further benefit the overall outcome of patients, but 
structured investigation of these techniques is needed. Although minimally invasive techniques avoid the 
need for open sternotomy, they also have a greater potential for malposition, the same cumulative 
incisional length, and still require an open sternotomy if the right ventricle fails.
259
 New technological 
breakthroughs are expected in the future (e.g. fully implantable pumps with transcutaneous energy 
transmission).
258
 Importantly, appropriate long‐term solutions for cases of severe right heart or 
biventricular failure remain an unmet need, as neither biventricular support with VADs or the total 
artificial heart can ensure a satisfactory quality of life and acceptable adverse event profile.  
Table 10. Overview of long‐term mechanical circulatory support devices 
Device Device characteristics Evidence from major clinical trials Major risks Ongoing/future studies 
     
HeartMate II (Thoratec, 
St. Jude, Abbott)151, 223, 
239-247 
Axial flow pump 
Implanted in pre‐peritoneal pocket, 
connected via inflow cannula to left 
ventricular apex, and via outflow cannula to 
ascending aorta 
BTT strategy (prospective, single‐arm, n=133): 75% survival 6 months, 68% 
survival 12 months239 
HeartMate II LVAD242 (randomized continuous flow vs. pulsatile): improved 2‐
year survival free of stroke or device failure for continuous flow vs. pulsatile 
ROADMAP151, 243 (observational, n=97 LVAD, n=103 OMM): LVAD associated 









Medtronic)235, 248-253, 257 
Continuous flow centrifugal pump 
Implanted and positioned completely within 
pericardial space, connected via driveline to 
controller 
Single‐arm (transplant candidates, NYHA class IV, n=50): 84% 1‐year survival248 
Post‐CE mark approval registry (n=254): 85% 1‐year survival, 73% 3‐year 
survival249 
ADVANCE (HeartWare vs. commercially available LVADs): non‐inferior to 
commercially available devices257; continued access protocol 84% 1‐year 
survival250 
ENDURANCE (randomized, open‐label, n=446 advanced HF ineligible for 
transplant, HeartWare vs. HeartMate II): non‐inferiority of HeartWare vs. other 
devices for survival at 2 years free from disabling stroke or device removal; higher 









HeartMate 3 (St. Jude, 
Abbott)234, 254-256, 258 
Continuous flow, centrifugal pump, bearing‐
less magnetically levitated rotor, artificial 
pulse 
Single arm (n=50, BTT and DT): 98% 30‐day survival, 92% 6‐month survival; 1‐
year survival similar to other devices254, 255 
MOMENTUM 3 (randomized, HeartMate 3 vs. HeartMate II, both BTT and DT, 
n=294): centrifugal flow pump non‐inferior to axial‐flow pump at 6 months; 
superiority also established (HR 0.55, 95% CI 0.32–0.95, P=0.04)234 
MOMENTUM 3 2‐year outcomes (n=366): 
• Survival free of disabling stroke or survival free of reoperation to replace/remove 
device: HR 0.46, 95% CI 0.31–0.69, P<0.001 (superiority)258 
• Rate of stroke: 10.1% vs. 19.2% (HR 0.47, 95% CI 0.27–0.84, P=0.02) 
No pump thrombosis in 
MOMENTUM 3 compared to 





MOMENTUM 3: randomized, 
HeartMate 3 vs. HeartMate II, both 
BTT and DT (long‐term outcomes)256 
     
 
ADVANCE, Evaluation of the HeartWare Left Ventricular Assist Device for the Treatment of Advanced Heart Failure; BTT, bridge to transplant; CI, confidence interval; DT, destination therapy; ENDURANCE, Evaluation of 
the HeartWare Ventricular Assist System for Destination Therapy of Advanced Heart Failure; HF, heart failure; HR, hazard ratio; LVAD, left ventricular assist device; MOMENTUM, Multicenter Study of MagLev Technology 
in Patients Undergoing Mechanical Circulatory Support Therapy with HeartMate 3; NYHA, New York Heart Association; OMM, optimal medical management; ROADMAP, Risk Assessment and Comparative Effectiveness of 
Left Ventricular Assist Device and Medical Management in Ambulatory Heart Failure Patients; RV, right ventricular. 
 
Palliative care of patients with advanced heart failure 
Optimal care of patients with advanced heart failure includes palliative care at their end‐of‐life period 
and whenever appropriate during the patient journey. Conventional therapy (cardiologic therapeutic 
approach) may not sufficiently reduce patient suffering and maximize quality of life. 
 
Successful palliative care must involve shared care through a multidisciplinary approach. Patients and 
their caregivers should be able to easily communicate with primary care, specialist palliative care services 
and the specialized advanced heart failure service, according to the resources of each centre.
9, 131, 260, 261
 
Aging, co‐morbid conditions, end‐organ damage, cognitive impairment, frailty and limited social support 
complicate heart failure management, and palliative care should address each of these components. End‐
of‐life decision making is even more challenging for patients with advanced heart failure when heart 
transplantation or long‐term MCS have failed.262 The PAL‐HF (Palliative Care in Heart Failure) trial, a 
single‐centre study of 150 patients, showed that interdisciplinary palliative care intervention in advanced 
heart failure patients resulted in greater benefits in quality of life, anxiety, depression and spiritual 
wellbeing compared with usual care alone.
263
 The SWAP‐HF (Social Worker‐Aided Palliative Care 
Intervention in High‐risk Patients with Heart Failure) trial showed that patients at high risk for mortality 
from heart failure frequently overestimate their life expectancy and a structured social worker‐led 
palliative care intervention enhances prognostic understanding and patient–physician communication 
regarding goals of care.
264 
 
Communication with advanced heart failure patients is complex. In heart failure, the trajectory of each 
patient is different. Stocker et al.
265
 showed that the majority of patients with heart failure reject the idea 
of heart failure as a terminal disease and prefer to focus on day‐to‐day management and maintenance, 
despite obvious deterioration in disease stage and needs over time. Common expectations pre‐ and post‐ 
heart transplant or MCS and potential complications should be discussed with patients and their 
caregivers, ideally, during the assessment and evaluation period for advanced heart failure therapies. 
Whenever possible, goals and preferences for end‐of life issues should be discussed, especially in patients 
treated with MCS for DT. Living will and advance directive preferences are useful, and patients should be 
encouraged to prepare the necessary documents. A comprehensive end‐of life plan of care for each patient 
should be available. This plan of care should be defined before MCS implantation or heart transplantation 
and revisited during the course of care.
262 
 
Patients with MCS as DT are particularly complex. A study at the Mayo Clinic on end‐of‐life care in 
long‐term MCS patients showed that 78% of the patients who died were hospitalized, and of these, 88% 
died in the intensive care unit. The main causes of death were multiorgan failure, haemorrhagic stroke, 
and heart failure.
266
 Goals of palliative care include management of physical symptoms (e.g. heart failure 
symptoms, pain, anxiety, depression, anorexia, constipation, and insomnia). Psychosocial and spiritual 
concerns should also be addressed.  
 
An important aspect is deciding when to discontinue advanced therapies (e.g. MCS, ICD, or 
immunosuppressive treatment). This decision should be the patient's whenever possible, or the patient's 
caregiver, family, or hospital ethics committee if the patient is unable to independently convey their 
decisions. Support can be discontinued in the hospital, in hospice, or at home depending on patient and 
family preferences, feasibility, and local resources. Nurses and health care personnel involved should be 
adequately trained to correctly deactivate devices and associated alarms and to provide comfort care to 
the patient and psychological support to the family and care team. 
  
Organizational issues for patient referral to advanced heart failure centres: hub and spoke network 
The broad spectrum of heart failure ranges from patients in the early stages of the disease largely 
managed by primary care physicians and secondary care cardiologists, to those who progress to more 
advanced stages and require specialized tertiary care. All heart failure patients should undergo regular 
follow‐up to detect progression of symptoms and disease. The criteria for referral to an advanced heart 
failure tertiary hub centre, i.e. those with capabilities for heart transplantation and MCS, must be based on 
need (i.e. indication) and eligibility (i.e. absence of contraindications) for those therapies, as well as the 
need for other advanced therapies for symptom management that may be unavailable at non‐specialized 
centres (e.g. UF, peritoneal dialysis). A useful mnemonic has been proposed to aid in the identification of 




Table 11. ‘I Need Help’—Markers of advanced heart failure 
   
I Inotropes  Previous or ongoing requirement for dobutamine, milrinone, dopamine, 
or levosimendan 
N NYHA class/ natriuretic peptide  Persisting NYHA class III or IV and/or persistently high BNP or NT‐
proBNP 
E End‐organ dysfunction  Worsening renal or liver dysfunction in the setting of heart failure 
E Ejection fraction  Very low ejection fraction <20% 
D Defibrillator shocks  Recurrent appropriate defibrillator shocks 
H Hospitalizations  More than 1 hospitalization with heart failure in the last 12 months 
E Edema/escalating diuretics  Persisting fluid overload and/or increasing diuretic requirement 
L Low blood pressure  Consistently low BP with systolic <90 to 100 mmHg 
P Prognostic medication  Inability to up‐titrate (or need to decrease/cease) ACEI, beta‐blockers, 
ARNIs, or MRAs 
   
 
ACEI, angiotensin‐converting enzyme inhibitor; ARNI, angiotensin receptor–neprilysin inhibitor; BNP, B‐type natriuretic peptide; 
BP, blood pressure; MRA, mineralocorticoid receptor antagonist; NT‐proBNP, N‐terminal pro‐B‐type natriuretic peptide; NYHA, 
New York Heart Association. 
Reprinted with permission from Baumwol.267 
Ideally, secondary care centres without advanced heart failure therapies (spoke centre) should liaise 
with a tertiary hub centre to develop a strong working relationship. Heart failure patients are then 
managed within this ‘hub and spoke’ continuum of care (Figure 2). Spoke centres are responsible for 
ensuring adherence to guideline‐directed therapy and that patients are referred to the tertiary hub centre at 





Figure 2. Conceptual structure of a hub and spoke model of care for patients with advanced heart failure (HF). This figure presents 
a concept for the structure of a hub and spoke model of care for patients with advanced HF. The roles for primary care, general 
cardiology (yellow), specialized HF (orange), and tertiary centres (red) are described. Solid lines reflect main lines of 
communication and referral. Dashed lines indicate secondary pathways for referral/communication (i.e. typically patients will first 
be referred to a specialized HF unit, but in some circumstances direct referral to the tertiary hub bypassing the specialized HF centre 
may be appropriate.) This model depicts an overview of the concept, which can be tailored to the local needs of the health care 
system. CRT, cardiac resynchronization therapy; ICD, implantable cardioverter‐defibrillator. 
Each country should define the standards and organizational structures for advanced heart failure 
tertiary hub centres regarding pathways for referring patients, which should be made available to every 
patient, in relation to his/her individual characteristics and needs.
260, 269-271
 The tertiary hub centre should 
ensure that spoke centres know how to communicate in an agile way (telephones, email address) 
including urgently, if necessary. Once a patient is referred for evaluation, the hub and spoke centre teams 
should jointly agree whether the consultation can be done on an outpatient basis or requires an inpatient 
transfer between the two hospitals.  
  
A protocol for the immediate management and safe transfer of unstable patients in cardiogenic shock 
must be developed and available at each tertiary hub centre, both for de novo patients and those with 
chronic, deteriorating heart failure. This protocol must be individualized, taking into account geographical 
considerations and resource availability at each spoke,
272-276 
including in some cases a team dispatched 
from the tertiary hub centre to retrieve the patient.
277, 278 
 
While the patient is on the waiting list for heart transplantation, decisions regarding cardiovascular 
care must be guided by the advanced heart failure team at the tertiary hub. However, the spoke centre 
physician has a key role in monitoring the patient's condition and implementing therapeutic decisions. 
Two‐way communication between spoke and hub centres is key for the successful management of the 
patient.
260
 Tertiary hub centres must provide education on advanced heart failure therapies and share their 
experience with spoke centres.  
Principles of shared care after heart transplantation or mechanical circulatory support 
As the numbers of patients receiving heart transplants are plateauing or declining, there is an 
increasing need for more long‐term MCS implantations. These advanced therapies should preferably be 
established within centres that offer both transplantation and MCS, although consensus has not been 
reached regarding this issue. Each hub and spoke centre should develop their own pathways for shared 
care. 
 
Follow‐up of patients after heart transplantation or implantation of MCS devices consists of both 
immediate post‐operative period and long‐term follow‐up. In the immediate post‐transplant or post‐MCS 
implantation, care should be shared among intensivists, surgeons and cardiologists. In the early phase, 
haemodynamic monitoring is of great importance for both therapies, allowing for more accurate titration 
of inotropic or vasodilator therapy. Haemodynamic monitoring, along with echocardiographic imaging, 
allows for early detection of some of the potential adverse events that might occur in the immediate post‐
operative period (e.g. hypovolaemia, tamponade, acute right heart failure). Echocardiography is an 
integral part of cardiac allograft evaluation as well as device optimization, which includes setting the 
pump speed of the device and adjusting medical therapy to achieve optimal unloading of the left ventricle, 
while balancing the preload provided to the right ventricle. 
 
Long‐term follow‐up of patients with advanced heart failure therapies is ideally done through the 
outpatient clinic. At each appointment for patients with long‐term MCS, patient history and physical 
examination and laboratory assessment (e.g. haemolysis, anaemia, liver, renal, and infection markers) 
should be performed, with special attention to blood pressure, signs of congestion, shortness of breath, 
potential infection, bleeding, thrombosis, and the patient's general condition. For a patient with long‐term 
MCS, the driveline exit site should be meticulously inspected for potential infection. The driveline, exit 
site, and other MCS system components should be examined to ensure their integrity. Blood pressure 
should be measured (preferably assisted with a Doppler ultrasonic device in patients with low pulsatility) 
and lowered if indicated. Blood pressure control is important since the risk of stroke is closely related to 
blood pressure for some devices like the HVAD. Mean arterial pressure should be maintained <90 
mmHg, and ideally <85 mmHg. Regular echocardiographic assessment should be performed, determining 
the need for device optimization, e.g. increasing or decreasing the device speed, depending on the 
position of the interventricular septum, opening of the aortic valve, or size of the left ventricle. Alarm 
history should be obtained at regular intervals. If possible, functional testing should be performed (e.g. 6‐
min walking distance). Special attention should be directed at maintaining adequate anticoagulation 
status, and if available self‐monitoring should be encouraged. Patients should be regularly educated on 
proper care of the driveline exit site. 
 
Post‐transplant patients should undergo a pre‐defined regimen of graft biopsies, titration of 
immunosuppressive and other therapies, rejection monitoring, assessment for infections, transplant 
coronary artery disease and/or cardiac allograft vasculopathy, immunosuppression side effects, and other 
potential complications including neoplasia, and co‐morbidities that require comprehensive treatment. 
Shared care with referral cardiologists and primary care physicians is needed. 
 
Treatment and follow‐up of patients who are post‐cardiac transplant or MCS recipients requires an 
interdisciplinary approach to meet the complex needs of these patients. In addition to the transplant 
cardiologist and MCS device specialist, a dedicated transplant/MCS device nurse is important to educate 
the patient and caregivers, as well as coordinate health care team members. A cardiac surgeon should also 
be included in case of surgical complications. For patients with MCS, driveline infection is primarily a 
surgical problem. Ideally, a nutritionist, physiotherapist, psychologist, psychiatrist, and general 
practitioner should also be a part of the team taking care of patients treated with advanced heart failure 
therapies. Depending on co‐morbidities and complications, other specialists should participate in shared 
care as appropriate. Highly experienced tertiary centres are required to provide this multidisciplinary 
approach to shared care and address the needs of heart failure patients managed with advanced therapies. 
Conclusion 
Advanced heart failure remains a major clinical challenge. Changes in the clinical characteristics and 
clinical practice of heart failure treatment have made it necessary to develop the present update of the 
original criteria for the definition of advanced heart failure. New biomarkers and imaging tools may allow 
better prognostic stratification and the assessment of mechanisms of disease progression. However, robust 
data are lacking from prospective, controlled trials demonstrating the clinical usefulness of these new 
methods. Once guideline‐directed management therapy is insufficient, the patient may benefit from 
advanced heart failure therapies. Inotropic agents have frequently been used as intermittent intravenous 
infusions, but no definitive outcome data from prospective, randomized trials are available and some 
studies have shown an association with increased mortality. Thus, these agents provide only symptomatic 
treatment or stabilization in unstable conditions. Impressive progress has been made with MCS devices. 
At least four devices are available for the immediate treatment of cardiogenic shock. Heart transplantation 
is considered the treatment of choice for eligible patients with excellent survival and quality of life, but it 
is limited by organ availability, graft dysfunction, and side effects of immunosuppression. Long‐term 
MCS can be used as a BTT or as DT. Recent improvement in the characteristics of MCS devices will 
broaden their indications and make them a valid alternative to medical treatment in patients with 
advanced heart failure. Lastly, palliative care is indicated when patients are ineligible for advanced heart 
failure therapies or after advanced therapies have been performed and patient progresses to end‐of‐life. 
Finally, it is important to note that no therapy in advanced heart failure is based on reliable prospective 
studies, and there is an urgent need to develop evidence‐based treatment algorithms to prolong life, 
increase life quality, and reduce the burden of hospitalization in this vulnerable patient population. 
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